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Abstract
The mechanistic Target of Rapamycin (mTOR) coordinates eukaryotic cell growth and 
metabolism with environmental inputs including nutrients and growth factors. Extensive research 
over the past two decades has established a central role for mTOR in regulating many fundamental 
cell processes, from protein synthesis to autophagy, and deregulated mTOR signaling is implicated 
in the progression of cancer and diabetes, as well as the aging process. Here, we review recent 
advances in our understanding of mTOR function, regulation, and importance in mammalian 
physiology. We also highlight how the mTOR-signaling network contributes to human disease, 
and discuss the current and future prospects for therapeutically targeting mTOR in the clinic.
Introduction
In 1964 a Canadian expedition to the isolated South Pacific island of Rapa Nui (also known 
as Easter Island) collected a set of soil samples with the goal of identifying novel 
antimicrobial agents. In bacteria isolated from one of these samples, Sehgal and colleagues 
discovered a compound with remarkable antifungal, immunosuppressive, and antitumor 
properties (Eng et. al. 1984; Martel et. al. 1977; Vezina et. al 1975). Further analysis of this 
compound, named rapamycin after its site of discovery (clinically referred to as sirolimus), 
revealed that it acts in part by forming a gain of function complex with the peptidyl-prolyl-
isomerase FKBP12 to inhibit signal transduction pathways required for cell growth and 
proliferation (Chung et. al., 1992).
Despite these insights, the full mechanism of action of rapamycin remained elusive until 
1994 when biochemical studies identified the mechanistic (formerly “mammalian”) Target 
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of Rapamycin (mTOR) as the direct target of the rapamycin-FKBP12 complex in mammals 
(Brown et. al. 1994; Sabatini et. al. 1994; Sabers et. al 1995), and revealed it to be the 
homolog of the yeast TOR/DRR genes that had previously been identified in genetic screens 
for rapamycin resistance (Cafferkey et. al. 1993; Heitman et. al. 1991; Kunz et. al. 1993).
In the more than two decades since these discoveries, studies from dozens of labs across the 
globe have revealed that the mTOR protein kinase nucleates a major eukaryotic signaling 
network that coordinates cell growth with environmental conditions and plays a fundamental 
role in cell and organismal physiology. Many aspects of mTOR function and regulation have 
only recently been elucidated, and many more questions remain unanswered. In this review, 
we provide an overview of our current understanding of the mTOR pathway and its role in 
growth, metabolism, and disease.
mTORC1 and mTORC2
mTOR is a serine/threonine protein kinase in the PI3K-related kinase (PIKK) family that 
forms the catalytic subunit of two distinct protein complexes, known as mTOR Complex 1 
(mTORC1) and 2 (mTORC2) (Fig. 1A). mTORC1 is defined by its three core components: 
mTOR, Raptor (regulatory protein associated with mTOR), and mLST8 (mammalian lethal 
with Sec13 protein 8, also known as GβL) (Fig. 1B, Kim et al. 2002; Hara et al. 2002; Kim 
et al. 2003). Raptor facilitates substrate recruitment to mTORC1 through binding to the TOR 
signaling (TOS) motif found on several canonical mTORC1 substrates (Nojima et al., 2003; 
Schalm et al., 2003), and, as described later, is required for the correct subcellular 
localization of mTORC1. mLST8 by contrast associates with the catalytic domain of 
mTORC1 and may stabilize the kinase activation loop (Yang et al. 2013), though genetic 
studies suggest it is dispensible for the essential functions of mTORC1 (Guertin et al., 
2006). In addition to these three core components, mTORC1 also contains the two inhibitory 
subunits PRAS40 (proline-rich Akt substrate of 40 kDa) (Sancak et al. 2007; Vander Haar et 
al. 2007; Wang et al. 2007) and DEPTOR (DEP domain containing mTOR interacting 
protein) (Peterson et al. 2009).
Structural studies of mTORC1 have yielded significant insights into its assembly, function, 
and perturbation by rapamycin. Cryo-EM reconstructions of both mTORC1 and yeast 
TORC1 have revealed that the complex forms a 1 mDa “lozenge”-shaped dimer, with the 
dimerization interface comprised of contacts between the mTOR HEAT repeats as well as 
between Raptor and mTOR (Fig. 1B, Aylett et al. 2016; Baretic et al., 2016; Yip et al. 2010). 
In addition, a crystal structure of the mTOR kinase domain bound to mLST8 showed that the 
rapamycin-FKBP12 complex binds to the FRB domain of mTOR to narrow the catalytic 
cleft and partially occlude substrates from the active site (Yang et al., 2013).
While the rapamycin-FKBP12 complex directly inhibits mTORC1, mTORC2 is 
characterized by its insensitivity to acute rapamycin treatment. Like mTORC1, mTORC2 
also contains mTOR and mLST8 (Fig. 1C). Instead of Raptor however, mTORC2 contains 
Rictor (rapamycin insensitive companion of mTOR), an unrelated protein that likely serves 
an analogous function (Jacinto et al. 2004; Sarbassov et al. 2004). mTORC2 also contains 
DEPTOR (Peterson et al. 2009), as well as the regulatory subunits mSin1 (Frias et al. 2006; 
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Jacinto et al. 2006; Yang et al. 2006) and Protor1/2 (Pearce et al. 2007; Thedieck et al. 2007; 
Woo et al., 2007). Although rapamycin-FKBP12 complexes do not directly bind or inhibit 
mTORC2, prolonged rapamycin treatment does abrogate mTORC2 signaling, likely due to 
the inability of rapamycin-bound mTOR to incorporate into new mTORC2 complexes 
(Lamming et al., 2012).
The mTOR Signaling Network
Downstream of mTORC1
In order to grow and divide, cells must increase production of proteins, lipids, and 
nucleotides while also suppressing catabolic pathways such as autophagy. mTORC1 plays a 
central role in regulating all of these processes, and therefore controls the balance between 
anabolism and catabolism in response to environmental conditions (Fig. 2, A and B). Here 
we review the critical substrates and cellular processes downstream of mTORC1 and how 
they contribute to cell growth. Most of the functions discussed here were identified and 
characterized in the context of mammalian cell lines, while the physiological context in 
which these processes are important will be discussed in greater detail later.
Protein synthesis—mTORC1 promotes protein synthesis largely through the 
phosphorylation of two key effectors, p70S6 Kinase 1 (S6K1) and eIF4E Binding Protein 
(4EBP) (Fig 2B). mTORC1 directly phosphorylates S6K1 on its hydrophobic motif site, 
Thr389, enabling its subsequent phosphorylation and activation by PDK1. S6K1 
phosphorylates and activates several substrates that promote mRNA translation initiation 
including eIF4B, a positive regulator of the 5′cap binding eIF4F complex (Holz et al., 
2005). S6K1 also phosphorylates and promotes the degradation of PDCD4, an inhibitor of 
eIF4B (Dorello et al. 2006), and enhances the translation efficiency of spliced mRNAs via 
its interaction with SKAR, a component of exon-junction complexes (Ma et al., 2008).
The mTORC1 substrate 4EBP is unrelated to S6K1 and inhibits translation by binding and 
sequestering eIF4E to prevent assembly of the eIF4F complex. mTORC1 phosphorylates 
4EBP at multiple sites to trigger its dissociation from eIF4E (Brunn et al., 1997; Gingras et 
al. 1999), allowing 5′cap-dependent mRNA translation to occur. Although it has long been 
appreciated that mTORC1 signaling regulates mRNA translation, whether and how it affects 
specific classes of mRNA transcripts has been debated. Global ribosome foot printing 
analyses however revealed that while acute mTOR inhibition moderately suppresses general 
mRNA translation, it most profoundly affects mRNAs containing pyrimidine-rich 5′ TOP or 
“TOP-like” motifs, which includes most genes involved in protein synthesis (Hsieh et al. 
2012; Thoreen et al. 2012).
Lipid, nucleotide, and glucose metabolism—Growing cells require sufficient lipids 
for new membrane formation and expansion. mTORC1 promotes de novo lipid synthesis 
through the sterol responsive element binding protein (SREBP) transcription factors, which 
control the expression of metabolic genes involved in fatty acid and cholesterol biosynthesis 
(Porstmann et al., 2008). While SREBP is canonically activated in response to low sterol 
levels, mTORC1 signaling can also activate SREBP independently through both an S6K1-
dependent mechanism (Duvel et al., 2010) as well as through the phosphorylation of an 
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additional substrate, Lipin1, which inhibits SREBP in the absence of mTORC1 signaling 
(Peterson et al., 2011).
Recent studies established that mTORC1 also promotes the synthesis of nucleotides required 
for DNA replication and ribosome biogenesis in growing and proliferating cells. mTORC1 
increases the ATF4-dependent expression of MTHFD2, a key component of the 
mitochondrial tetrahydrofolate cycle that provides one-carbon units for purine synthesis 
(Ben-Sahra et al., 2016). Additionally, S6K1 phosphorylates and activates carbamoyl-
phosphate synthetase (CAD), a critical component of the de novo pyrimidine synthesis 
pathway (Ben-Sahra et al., 2013; Robataille et al., 2013).
mTORC1 also facilitates growth by promoting a shift in glucose metabolism from oxidative 
phosphorylation to glycolysis, which likely facilitates the incorporation of nutrients into new 
biomass. mTORC1 increases the translation of the transcription factor HIF1α (Fig. 2C), 
which drives the expression of several glycolytic enzymes such as phospho-fructo kinase 
(PFK) (Duvel et al., 2010). Furthermore, mTORC1-dependent activation of SREBP leads to 
increased flux through the oxidative pentose phosphate pathway (PPP), which utilizes 
carbons from glucose to generate NADPH and other intermediary metabolites needed for 
proliferation and growth.
Regulation of protein turnover—In addition to the various anabolic processes outlined 
above, mTORC1 also promotes cell growth by suppressing protein catabolism (Fig. 1B), 
most notably autophagy. An important early step in autophagy is the activation of ULK1, a 
kinase that forms a complex with ATG13, FIP2000, and ATG101 and drives autophagosome 
formation. Under nutrient replete conditions, mTORC1 phosphorylates ULK1, thereby 
preventing its activation by AMPK, a key activator or autophagy (Kim et al., 2011). Thus, 
the relative activity of mTORC1 and AMPK in different cellular contexts largely determines 
the extent of autophagy induction. mTORC1 also regulates autophagy in part by 
phosphorylating and inhibiting the nuclear translocation of the transcription factor TFEB, 
which drives the expression of genes for lysosomal biogenesis and the autophagy machinery 
(Martina et al., 2012; Roçzniak-Ferguson et al., 2012; Settembre et al., 2012).
The second major pathway responsible for protein turnover is the ubiquitin-proteasome 
system (UPS), through which proteins are selectively targeted for degradation by the 20S 
proteasome following covalent modification with ubiquitin. Two recent studies found that 
acute mTORC1 inhibition rapidly increases proteasome-dependent proteolysis through 
either a general increase in protein ubiquitylation, or an increased abundance of proteasomal 
chaperones via inhibition of Erk5 (Fig. 2B, Rousseau et al., 2016, Zhao et al., 2015). 
However, another study found that genetic hyper-activation of mTORC1 signaling also 
increases proteasome activity, through elevated expression of proteasome subunits 
downstream of Nrf1 (Zhang et al., 2014). One possible explanation for this discrepancy is 
that while acute mTORC1 inhibition promotes proteolysis to restore free amino acid pools, 
prolonged mTORC1 activation also triggers a compensatory increase in protein turnover to 
balance the increased rate of protein synthesis. Given that the UPS is responsible for the 
majority of protein degradation in human cells, precisely how mTORC1 regulates this 
process is an important question going forward.
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Downstream of mTORC2
While mTORC1 regulates cell growth and metabolism, mTORC2 instead controls 
proliferation and survival primarily by phosphorylating several members of the AGC 
(PKA/PKG/PKC) family of protein kinases (Fig. 2D). The first mTORC2 substrate to be 
identified was PKCα, a regulator of the actin cytoskeleton (Jacinto et al., 2004, Sarbassov et 
al., 2004). More recently, mTORC2 has also been shown to phosphorylate several other 
members of the PKC family, including PKCδ (Gan et al., 2012), PKCζ (Li and Gao, 2014), 
as well as PKCγ and PKCε (Thomanetz et al., 2013), all of which regulate various aspects 
of cytoskeletal remodeling and cell migration.
The most important role of mTORC2 however is likely the phosphorylation and activation of 
Akt, a key effector of insulin/PI3K signaling (Sarbassov et al., 2005). Once active, Akt 
promotes cell survival, proliferation, and growth through the phosphorylation and inhibition 
of several key substrates including the FoxO1/3a transcription factors, the metabolic 
regulator GSK3β, and the mTORC1 inhibitor TSC2. However while mTORC2-dependent 
phosphorylation is required for Akt to phosphorylate some substrates in vivo, such as 
FoxO1/3a, it is dispensable for the phosphorylation of others including TSC2 (Guertin et al., 
2006; Jacinto et. al., 2006). Finally, mTORC2 also phosphorylates and activates SGK1, 
another AGC-kinase that regulates ion transport as well as cell survival (Garcia-Martinez 
and Alessi, 2008).
Upstream of mTORC1
The mTORC1-dependent shift towards increased anabolism should only occur in the 
presence of pro-growth endocrine signals as well as sufficient energy and chemical building 
blocks for macromolecular synthesis. In mammals, these inputs are largely dependent on 
diet, such that mTORC1 is activated following feeding to promote growth and energy 
storage in tissues such as the liver and muscle, but inhibited during fasting conserve limited 
resources. Here we discuss the cellular pathways upstream of mTORC1 and the mechanisms 
through which they control mTORC1 activation.
Growth Factors—Studies of rapamycin in the early 1990s revealed that mTORC1 is a 
downstream mediator of several growth factor and mitogen-dependent signaling pathways, 
all of which inhibit a key negative regulator of mTORC1 signaling known as the Tuberous 
Sclerosis Complex (TSC) complex. TSC is a heterotrimeric complex comprised of TSC1, 
TSC2, and TBC1D7 (Dibble et al., 2012), and functions as a GTPase activating protein 
(GAP) for the small GTPase Rheb (Inoki et al., 2003; Tee et al., 2003), which directly binds 
and activates mTORC1 (Long et al., 2005; Sancak et al., 2007). Although Rheb is an 
essential activator of mTORC1, exactly how it stimulates mTORC1 kinase activity remains 
unknown.
Numerous growth factor pathways converge on TSC (Fig. 2A, reviewed in Huang and 
Manning, 2008), including the insulin/insulin-like growth factor-1 (IGF-1) pathway, which 
triggers the Akt-dependent multisite phosphorylation of TSC2. This phosphorylation inhibits 
TSC by dissociating it from the lysosomal membrane, where at least some fraction of 
cellular Rheb localizes (Menon et al., 2014). Similarly, receptor tyrosine kinase-dependent 
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Ras signaling activates mTORC1 via the MAP Kinase Erk and its effector p90RSK, both of 
which also phosphorylate and inhibit TSC2. It is unclear however whether these inputs also 
control the localization of TSC, or rather inhibit its GAP activity through a distinct 
mechanism. Additional growth factor pathways upstream of TSC include Wnt and the 
inflammatory cytokine TNFα, both of which activate mTORC1 through the inhibition of 
TSC1. Precisely how the TSC complex integrates these numerous signals and their relative 
impact on mTORC1 activity in various contexts however remains an open question.
Energy, oxygen, and DNA damage—mTORC1 also responds to intracellular and 
environmental stresses that are incompatible with growth such as low ATP levels, hypoxia, 
or DNA damage. A reduction in cellular energy charge, for example during glucose 
deprivation, activates the stress responsive metabolic regulator AMPK, which inhibits 
mTORC1 both indirectly, through phosphorylation and activation of TSC2, as well as 
directly through the phosphorylation of Raptor (Gwinn et al., 2008; Inoki et al., 2003b; 
Shaw et al., 2004). Interestingly, glucose deprivation also inhibits mTORC1 in cells lacking 
AMPK, through inhibition of the Rag GTPases, suggesting that mTORC1 senses glucose 
through more than one mechanism (Efeyan et al., 2013; Kalender et al., 2010). Similarly, 
hypoxia inhibits mTORC1 in part through AMPK activation, but also through the induction 
of REDD1 (Regulated in DNA damage and development 1), which activates TSC 
(Brugarolas et al., 2004). Finally, the DNA damage-response pathway inhibits mTORC1 
through the induction of p53 target genes including the AMPK regulatory subunit 
(AMPKβ), PTEN, and TSC2 itself, all of which increase TSC activity (Feng et al., 2007).
Amino Acids—In addition to glucose-dependent insulin release, feeding also leads to an 
increase in serum amino acid levels due to the digestion of dietary proteins. As amino acids 
are not only essential building blocks of proteins but also sources of energy and carbon for 
many other metabolic pathways, mTORC1 activation is tightly coupled to diet-induced 
changes in amino acid concentrations.
A breakthrough in the understanding of amino acid sensing by mTORC1 came with the 
discovery of the heterodimeric Rag GTPases as components of the mTORC1 pathway (Kim 
et al., 2008; Sancak et al., 2008). The Rags are obligate heterodimers of RagA or RagB with 
RagC or RagD, and are tethered to the lysosomal membrane through their association with 
the pentameric Ragulator complex comprised of MP1, p14, p18, HBXIP and c7ORF59 
(Sancak et al., 2010; Bar-Peled et al., 2012). Amino acid stimulation converts the Rags to 
their active nucleotide-bound state, allowing them to bind Raptor and recruit mTORC1 to 
the lysosomal surface, where Rheb is also located. This pathway architecture therefore forms 
an “AND-gate”, whereby mTORC1 signaling is only on when both the Rags and Rheb are 
activated, explaining why both growth factors and amino acids are required for mTORC1 
activation.
Despite these insights, the identities of the direct amino acid sensors upstream of mTORC1 
have been elusive until very recently. It is now clear that mTORC1 senses both intra-
lysosomal and cytosolic amino acids through distinct mechanisms. Amino acids inside the 
lysosomal lumen alter the Rag nucleotide state through a mechanism dependent on the 
lysosomal v-ATPase, which interacts the Ragulator-Rag complex to promote the guanine-
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nucleotide exchange factor (GEF) activity of Ragulator towards RagA/B (Zoncu et al., 2011; 
Bar-Peled et al., 2012). The lysosomal amino acid transporter SLC38A9 interacts with the 
Rag-Ragulator-v-ATPase complex and is required for arginine to activate mTORC1, making 
it a promising candidate to be a lysosomal amino acid sensor (Jung et al., 2015; Rebsamen et 
al., 2015; Wang et al., 2015).
Cytosolic leucine and arginine signal to mTORC1 through a distinct pathway comprised of 
the GATOR1 and GATOR2 complexes (Bar-Peled et al., 2013). GATOR1 consists of 
DEPDC5, Nprl2 and Nprl3, and inhibits mTORC1 signaling by acting as a GAP for 
RagA/B. The recently identified KICSTOR complex (consisting of Kaptin, ITFG2, 
c12orf66, and SZT2) tethers GATOR1 to the lysosomal surface and is necessary for the 
appropriate control of the mTORC1 pathway by nutrients (Wolfson et al., 2017). GATOR2 
by contrast is a pentameric complex comprised of Mios, WDR24, WDR59, Seh1L and 
Sec13, and is a positive regulator of mTORC1 signaling that interacts with GATOR1 at the 
lysosomal membrane (Bar-Peled et al., 2013).
An important insight into the mechanism of cytosolic amino acid sensing came with the 
identification of Sestrin2 as a GATOR2 interacting protein that inhibits mTORC1 signaling 
under amino acid deprivation (Chantranupong et al., 2014; Parmigiani et al., 2014). 
Subsequent biochemical and structural analyses established that Sestrin2 is a direct leucine 
sensor upstream of mTORC1 that binds and inhibits GATOR2 function in the absence of 
leucine, and dissociates from it upon leucine binding (Saxton et al., 2016a; Wolfson et al., 
2016). Furthermore, the affinity of Sestrin2 for leucine determines the sensitivity of 
mTORC1 signaling to leucine in cultured cells, demonstrating that Sestrin2 is the primary 
leucine sensor for mTORC1 in this context. It remains to be seen whether and in what 
tissues leucine concentrations fluctuate within the relevant range to be sensed by Sestrin2 in 
vivo, as the levels of interstitial or cytosolic leucine are unknown. Interestingly, another 
recent study found that Sestrin2 is transcriptionally induced upon prolonged amino acid 
starvation via the stress-responsive transcription factor ATF4 (Ye et al., 2015), suggesting 
that Sestrin2 functions as both an acute leucine sensor as well as an indirect mediator of 
prolonged amino acid starvation.
Cytosolic arginine also activates mTORC1 through the GATOR1/2-Rag pathway by directly 
binding the recently identified arginine sensor CASTOR1 (Cellular Arginine Sensor for 
mTORC1). Much like Sestrin2, CASTOR1 binds and inhibits GATOR2 in the absence of 
arginine, and dissociates upon arginine binding to enable the activation of mTORC1 
(Chantranupong et al., 2016; Saxton et al., 2016b). Thus, both leucine and arginine stimulate 
mTORC1 activity at least in part by releasing inhibitors from GATOR2, establishing 
GATOR2 as a central node in the signaling of amino acids to mTORC1. Importantly 
however, the molecular function of GATOR2 and the mechanisms through which Sestrin2 
and CASTOR1 regulate it are unknown.
Several additional mechanisms through which amino acids regulate mTORC1 signaling have 
also recently been reported, including the identification of the Folliculin-FNIP2 complex as 
a GAP for RagC/D that activates mTORC1 in the presence of amino acids (Petit et al., 2013; 
Tsun et al., 2013). Another study found that the amino acid glutamine, which is utilized as a 
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nitrogen and energy source by proliferating cells, activates mTORC1 independently of the 
Rag GTPases through the related Arf family GTPases (Jewell et al., 2015). Finally, a recent 
report found that the small polypeptide SPAR associates with the v-ATPase-Ragulator 
complex to suppress mTORC1 recruitment to lysosomes, though how this occurs is unclear 
(Matsumoto et al., 2016).
Upstream of mTORC2
In contrast to mTORC1, mTORC2 primarily functions as an effector of insulin/PI3K 
signaling (Fig. 2A). Like most PI3K regulated proteins, the mTORC2 subunit mSin1 
contains a phosphoinositide-binding PH domain that is critical for the insulin-dependent 
regulation of mTORC2 activity. The mSin1 PH domain inhibits mTORC2 catalytic activity 
in the absence of insulin, and this autoinhibition is relieved upon binding to PI3K-generated 
PIP3 at the plasma membrane (Liu et al., 2015). mSin1 can also be phosphorylated by Akt, 
suggesting the existence of a positive-feedback loop whereby partial activation of Akt 
promotes the activation of mTORC2, which in turn phosphorylates and fully activates Akt 
(Yang et al., 2015). Another study found that PI3K promotes the association of mTORC2 
with ribosomes to activate its kinase activity, although the mechanistic basis for this is 
unclear (Zinzalla et al., 2011).
Unexpectedly, mTORC2 signaling is also regulated by mTORC1, due to the presence of a 
negative feedback loop between mTORC1 and insulin/PI3K signaling. mTORC1 
phosphorylates and activates Grb10, a negative regulator of insulin/IGF-1 receptor signaling 
upstream of Akt and mTORC2, (Hsu et al., 2011; Yu et al., 2011), while S6K1 also 
suppresses mTORC2 activation through the phosphorylation-dependent degradation of 
insulin receptor substrate 1 (IRS1) (Harrington et al., 2004; Shah et al., 2004). This negative 
feedback regulation of PI3K and mTORC2 signaling by mTORC1 has numerous 
implications for the pharmacological targeting of mTOR in disease, discussed below.
Evolutionary conservation of the TOR pathway
One remarkable feature of the TOR pathway is its conservation as a major growth regulator 
in virtually all eukaryotes. Like mammals, S. cerevisiae also have two distinct TOR 
containing complexes, TORC1 and TORC2 (reviewed in Loewith and Hall, 2011) as well as 
homologs of Raptor (Kog1), mLST8 (Lst8), Rictor (Avo3), and mSin1 (Avo1), although 
several additional components are yeast or mammal specific. Furthermore yeast TORC1 also 
primarily controls cell growth and anabolic metabolism, including the activation of protein 
synthesis and inhibition of autophagy, while yeast TORC2 primarily functions to activate 
AGC family kinases such as YPK1, the homologue of mammalian SGK1.
As with mTORC1, yeast TORC1 also senses and responds to a diverse array of 
environmental stimuli, although the specific inputs and upstream signaling components 
differ in several respects, as one would expect given the vastly different environmental 
conditions that are relevant for these organisms (Fig. 3A). For example, hormone and growth 
factor receptor signaling are developments specific to multicellular organisms, and the 
mTORC1 regulator TSC is not found in S. cerevisiae. Instead, yeast TORC1 appears to be 
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primarily sensitive to direct biosynthetic inputs such as carbon, nitrogen and phosphate 
sources.
Unlike mammals, yeast are able to synthesize all 20 amino acids, and starvation of 
individual amino acids like leucine or arginine does not inhibit TORC1 signaling in wild-
type strains. Leucine deprivation does inhibit TORC1 in leucine-auxotrophs however (Binda 
et al., 2009), suggesting there may be a mechanism for signaling amino acid levels to 
TORC1, although this could also be due to the sensing of nitrogen sources that are perturbed 
in this context. Both the Rag GTPases and the GATOR1/2 complexes are present in S. 
cerevisiae in the form of Gtr1/2 and the SEACIT/SEACAT complexes, respectively (Fig. 3A, 
Panchaud et al., 2009), while the yeast EGO Complex is a structural homolog of Ragulator 
that interacts with Gtr1/2 and likely serves an analogous function (Powis et al., 2015; Zhang 
et al., 2012). In contrast to mammals however, amino acids do not affect the localization of 
yeast TORC1, which is constitutively bound to the Gtr-Ego complex at the vacuolar 
membrane (Binda et al., 2009), suggesting an alternative sensing mechanism exists. 
Consistent with this, the mammalian amino acid sensors SLC38A9, Sestrin2, and 
CASTOR1 all lack clear homologs in yeast.
While most of the TORC1 pathway components are also well conserved in other 
multicellular model organisms, the direct amino acid sensors appear to have diverged (Fig. 
3B). For example, although both SLC38A9 and CASTOR1 are conserved throughout many 
metazoan lineages, they are absent in D. melanogaster, suggesting that this organism either 
does not sense arginine or does so through a distinct mechanism. Both D. melanogaster and 
C. elegans do have a Sestrin homolog however, and dmSestrin also binds leucine (Wolfson et 
al., 2016). Interestingly, both ceSestrin and dmSestrin contain subtle differences in their 
leucine binding pockets predicted to reduce their affinity for leucine relative to human 
Sestrin2, likely enabling the sensing of physiologically relevant leucine levels in these 
organisms (Saxton et al., 2016a).
Physiological roles of mTOR
Changes in available energy sources following fasting or feeding require alterations in whole 
body metabolism to maintain homeostasis. Under starvation, levels of nutrients and growth 
factors drop, inducing a catabolic state in which energy stores are mobilized to maintain 
essential functions (Fig. 4A). Alternatively, high levels of nutrients in the fed-state trigger a 
switch towards anabolic growth and energy storage. Consistent with its role in coordinating 
anabolic and catabolic metabolism at the cellular level, physiological studies in mice have 
revealed that mTOR signaling is essential for proper metabolic regulation at the organismal 
level as well. Importantly, however, constitutive mTOR activation is also associated with 
negative physiological outcomes, indicating that the proper modulation of mTOR signaling 
in response to changing environmental conditions is crucial (Fig. 4B).
Glucose homeostasis
When blood glucose levels drop, the liver activates a compensatory response involving the 
induction of autophagy, gluconeogenesis, and the release of alternative energy sources in the 
form of ketone bodies. Several lines of evidence suggest that regulation of mTORC1 
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signaling is crucial for the response of the liver to diet. For example, mice with liver specific 
deletion of TSC1, which have constitutively activated mTORC1 signaling, fail to generate 
ketone bodies during fasting due to sustained mTORC1-dependent suppression of PPARa, a 
transcriptional activator of ketogenic genes (Sengupta et al., 2010). The importance of 
inhibiting mTORC1 in the liver during fasting has also been observed through the generation 
mice with a while-body knock-in of a constitutively active allele of RagA (RagAGTP). 
Although they develop normally, these mice die rapidly after birth due to an inability to 
maintain blood glucose levels during the perinatal fasting period (Efeyan et al., 2013). 
Further analysis of these mice revealed that sustained mTORC1 activity during this fasting 
period prevents the induction of autophagy in the liver, which is critical for supplying free 
amino acids for gluconeogenesis. As a result, RagAGTP mice display fatal hypoglycemia in 
response to fasting, consistent with a similar phenotype in autophagy deficient mice (Kuma 
et al., 2004).
mTORC1 signaling also plays an important role in glucose homeostasis by regulating 
pancreatic β-cell function. Studies using β-cell specific TSC2 knock out (β-TSC2KO) mice 
revealed that hyperactivation of mTORC1 has a biphasic effect on β-cell function, with 
young β-TSC2KO mice exhibiting increased β-cell mass, higher insulin levels, and improved 
glucose tolerance (Mori et al., 2009; Shigeyama et al., 2008). This effect is reversed in older 
β-TSC2KO mice, which more rapidly develop reduced β-cell mass, lower insulin levels, and 
hyperglycemia. Thus, high mTORC1 activity in the pancreas is initially beneficial for 
glucose tolerance, but also leads to a faster decline in β-cell function over time (Fig. 4C).
This biphasic effect of mTORC1 signaling is reminiscent of diet-induced (type 2) diabetes 
progression, in which pancreatic β-cells initially expand and produce more insulin to 
compensate for an increased glycemic load, but eventually undergo exhaustion. Indeed, 
obese or high fat diet (HFD) treated mice have high mTORC1 signaling in many tissues, 
including the pancreas, likely due to increased levels of circulating insulin, amino acids, and 
pro-inflammatory cytokines (Khamzina et al., 2005). Increased mTORC1 signaling in these 
tissues also contributes to peripheral insulin resistance due to enhanced feedback inhibition 
of insulin/PI3K/Akt signaling, which is prevented in mice lacking S6K1/2 (Fig. 4D, Um et 
al., 2004).
That mTORC1 hyperactivation from genetic or dietary manipulation results in insulin 
resistance has led many to speculate that mTORC1 inhibitors could improve glucose 
tolerance and protect against type 2 diabetes. Paradoxically, however, chronic 
pharmacological inhibition of mTORC1 using rapamycin has the opposite effect, causing 
insulin resistance and impaired glucose homeostasis (Fig. 4D, Cunningham et al., 2007). 
This result is explained at least in part by the fact that prolonged rapamycin treatment also 
inhibits mTORC2 signaling in vivo (Lamming et al., 2012). As mTORC2 directly activates 
Akt downstream of insulin/PI3K signaling, it is not surprising that mTORC2 inhibition 
disrupts the physiological response to insulin. Consistent with this, liver specific Rictor 
knockout mice have severe insulin resistance and glucose intolerance (Hagiwara et al., 2012; 
Yuan et al., 2012), as do mice lacking Rictor in the muscle or fat (Kumar et al., 2008 & 
2010).
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Muscle mass and function
Although the importance of mTOR signaling in promoting muscle growth is well 
appreciated by basic scientists and bodybuilders alike, the mechanisms underlying this 
process are still poorly understood, in part due to the difficulty of genetically manipulating 
multinucleate myocytes in vivo. Nonetheless, early studies of mTOR signaling in the muscle 
revealed that mTORC1 activation is associated with muscle hypertrophy (Bodine et al., 
2001) and that both IGF-1 and leucine promote hypertrophy through the activation of 
mTORC1 signaling in cultured cells and in mice (Anthony et al., 2000; Rommel et al., 
2001). Moreover, muscle specific Raptor knockout mice display severe muscle atrophy and 
reduced body weight leading to early death (Bentzinger et al., 2008). This dramatic 
phenotype is also observed in muscle specific mTOR knockout mice, but not Rictor deficient 
mice, suggesting that the critical functions of mTOR in skeletal muscle are through 
mTORC1 (Bentzinger et al., 2008; Risson et al., 2009).
While acute activation of mTORC1 signaling in vivo does promote muscle hypertrophy in 
the short-term (Bodine et al., 2001) chronic mTORC1 activation in the muscle through loss 
of TSC1 also results in severe muscle atrophy, low body mass, and early death, primarily 
due to a lack the inability to induce autophagy in this tissue (Fig. 4D, Castets et al, 2013). 
Considering that turnover of old or damaged tissue plays a critical role in muscle growth, 
these results suggest that alternating periods of high and low mTORC1 activity, as occurs 
with normal feeding and fasting cycles, is essential for maintaining optimal muscle health 
and function (Fig. 4F).
An accumulating body of evidence suggests that muscle contraction also activates mTORC1 
in the muscle; potentially explaining at least in part how increased muscle use promotes 
anabolism (Baar and Esser, 1999). A recent study found that mechanical stimuli activate 
mTORC1 signaling by inducing the phosphorylation of Raptor (Frey et al., 2014), although 
how this occurs in not clear. Understanding how mTORC1 can integrate the distinct signals 
from insulin, amino acids, and mechanical force in the muscle will be an important goal 
going forward and may inform approaches for treating muscle wasting disorders such as 
those associated with disuse and aging.
Adipogenesis and lipid homeostasis
Many studies over the last two decades also reveal a role for mTOR in promoting adipocyte 
formation and lipid synthesis in response to feeding and insulin (Fig. 4D, reviewed in 
Lamming and Sabatini, 2013). mTORC1 promotes adipogenesis and enhanced lipogenesis 
in cell culture and in vivo, consistent with adipocyte-specific raptor knock out (Ad-RapKO) 
mice displaying lipodystrophy and hepatic steatosis (Lee et al., 2016). However, the role of 
mTORC1 in adipose is complicated by the fact that Ad-RapKO mice are also resistant to diet 
induced obesity due to reduced adipogenesis, suggesting mTORC1 inhibition in this tissue 
can have both positive and negative effects (Polak et al., 2008).
Similarly, the loss of mTORC2 activity in adipocytes primarily results in insulin resistance 
due to reduced Akt activity (Kumar et al., 2010), but also in less lipid synthesis in part due to 
reduced expression of ChREBPβ, a master transcription factor for lipogenic genes (Tang et 
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al., 2016). mTORC2 has also been shown to promote lipogenesis in the liver as well, 
suggesting a general role for mTORC2 in lipid synthesis (Hagiwara et al., 2012; Yuan et al., 
2012) Thus, both mTORC1 and mTORC2 play important roles in multiple aspects of 
adipocyte function and lipid metabolism.
Immune function
Early studies into the biological properties of rapamycin revealed a role in blocking 
lymphocyte proliferation, leading to its eventual clinical approval as an immunosuppressant 
for kidney transplants in 1999. The immunosuppressive action of rapamycin is largely 
attributed to its ability to block T-cell activation, a key aspect of the adaptive immune 
response (reviewed in Powell et al., 2012). Mechanistically, mTORC1 facilitates the switch 
towards anabolic metabolism that is required for T-cell activation and expansion, and lies 
downstream of several activating signals present in the immune microenvironment including 
IL-2, the co-stimulatory receptor CD28, as well as amino acids. Interestingly, mTORC1 
inhibition during antigen presentation results in T-cell anergy, whereby cells fail to activate 
upon subsequent antigen exposure (Zheng et al., 2007). As the induction of T-cell anergy via 
nutrient depletion or other inhibitory signals is a mechanism utilized by tumors in immune 
evasion, these data suggest that promoting mTORC1 activation in immune cells may 
actually be beneficial in some contexts, such as cancer immunotherapy.
Recent studies have also found a role for mTORC1 in influencing T-cell maturation, as 
rapamycin promotes the differentiation and expansion of CD4+FoxP3+ Regulatory T-cells 
and CD8+ memory T-cells while suppressing CD8+ and CD4+ effector T-cell populations 
(Araki et al., 2009; Haxhanisto et al., 2008), consistent with the metabolic profiles of these 
cell types. Indeed, a recent report found that during the asymmetric division of activated 
CD8+ T-cells, high mTORC1 activity is high in the “effector-like” daughter cell, but low in 
the “memory-like” daughter cell, due to the asymmetric partitioning of amino acid 
transporters (Polizzi et al., 2016; Verbist et al., 2016). Thus, the role of mTOR signaling in 
the immune system is clearly more complex than previously thought. Given the current 
clinical use of mTOR inhibitors in both immunosuppression and cancer, a more 
comprehensive understanding of how mTOR signaling influences overall immune responses 
in vivo will be a critical goal going forward.
Brain function
mTOR has also emerged as an important regulator of numerous neurological processes 
including neural development, circuit formation, and the neural control of feeding (reviewed 
in Lipton and Sahin, 2014). The deletion of either Raptor or Rictor in neurons causes 
reduced neuron size, and early death, suggesting that signaling by both mTORC1 and 
mTORC2 is important for proper brain development. Conversely, the impact of hyperactive 
mTORC1 signaling in the brain is best observed in human patients with Tuberous Sclerosis 
Complex (TSC), who exhibit a range of debilitating neurological disorders including 
epilepsy, autism, and the presence of benign brain tumors.
The fact that mTORC1 hyperactivation in TSC patients correlates with a high occurrence of 
epileptic seizures (90% of TSC patients) and autistic traits (50%) suggests that deregulated 
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mTORC1 signaling may also be involved in epilepsy and autism more generally. Indeed, 
mTORC1 hyperactivation in mice through neural loss of Tsc1 or Tsc2 leads to severe 
epileptic seizures that are prevented by rapamycin treatment (Zeng et al., 2008), and 
mutations in components of the GATOR1 and KICSTOR complexes have been linked to 
epilepsy in humans (Basel-Vanagaite et al., 2013; Ricos et al., 2016).
The importance of mTORC1 in this tissue stems in part from its role in promoting activity-
dependent mRNA translation near synapses, a critical step in neuronal circuit formation. 
Consistent with this, the NMDA receptor antagonist ketamine acutely activates mTORC1 
signaling in mouse neurons, which coincides with an increased translation of synaptic 
proteins (Li et al., 2010). The role of mTORC1 in regulating autophagy is likely also 
important, as autophagy dysfunction is strongly implicated in the pathogenesis of 
neurodegenerative disorders including Parkinson’s disease and Alzheimer’s disease (AD). 
Inhibiting mTOR signaling has beneficial effects on mouse models of AD (Spilman et al., 
2010), and it remains to be seen whether similar results will be seen in humans.
mTOR in Cancer
As discussed above, mTORC1 functions as a downstream effector for many frequently 
mutated oncogenic pathways including the PI3K/Akt pathway as well as the 
Ras/Raf/Mek/Erk (MAPK) pathway, resulting in mTORC1 hyperactivation in a high 
percentage of human cancers (Fig. 5A). Furthermore, the common tumor suppressors TP53 
and LKB1 are negative regulators of mTORC1 upstream of TSC1 and TSC2, which are also 
tumor suppressors originally identified through genetic analysis of the familial cancer 
syndrome TSC. Several components of the nutrient sensing input to mTORC1 have also 
been implicated in cancer progression, including all three subunits of the GATOR1 complex, 
which are mutated with low frequency in glioblastoma (Bar-Peled et al., 2013), as well as 
RagC, which was recently found to be mutated at high frequency (~18%) in follicular 
lymphoma (Okosun et al., 2015). Additionally, mutations in the gene encoding folliculin 
(FLCN) are the causative lesion in the Birt-Hogg-Dube hereditary cancer syndrome 
(Nickerson et al., 2002), which manifests similarly to TSC. Finally, mutations in MTOR 
itself are also found in a variety of cancer subtypes, consistent with a role for mTOR in 
tumorigenesis (Grabiner et al., 2014; Sato et al., 2010).
mTORC2 signaling is also implicated in cancer largely due to its role in activating Akt, 
which drives pro-proliferative processes such as glucose uptake and glycolysis while also 
inhibiting apoptosis. Indeed, at least some PI3K/Akt driven tumors appear to rely on 
mTORC2 activity, as Rictor is essential in mouse models of prostate cancer driven by PTEN 
loss, as well as in human prostate cancer cell lines that lack PTEN (Guertin et al., 2009; 
Hietakangas et al., 2008).
While many mTORC1-driven processes likely contribute to tumorigenesis, the translational 
program initiated by the phosphorylation of 4EBP is likely the most critical, at least in 
mouse models of Akt-driven prostate cancer and T-cell lymphoma (Hsieh et al., 2010 & 
2012). Consistent with this, a variety of Akt and Erk driven cancer cell lines are dependent 
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on 4EBP phosphorylation, and the ratio of 4EBP to eIF4E expression correlates well with 
their sensitivity to mTOR inhibitors (Alain et al., 2012; She et al., 2010).
The first mTOR inhibitors approved for use in cancer were a class of rapamycin derivatives 
known as “rapalogs”. The rapalog temsirolimus (Pfizer) was first approved for treatment of 
advanced renal cell carcinoma in 2007, followed by everolimus (Novartis) in 2009. Although 
a small number of “extraordinary responders” have been reported, these rapalogs have been 
less successful in the clinic than anticipated from pre-clinical cancer models.
Several explanations for this lack of efficacy have been suggested. The first came with the 
realization that, as allosteric inhibitors, the rapalogs block the phosphorylation of some but 
not all mTORC1 substrates (Fig. 5B, Choo et al., 2008; Feldman et al., 2009; Kang et al., 
2013; Thoreen et al., 2009). In particular, the phosphorylation of 4EBP is largely insensitive 
to rapamycin. Second, inhibiting mTORC1 releases the negative feedback on insulin/
PI3K/Akt signaling, and therefore may paradoxically promote cell survival and prevent 
apoptosis in some contexts. Indeed, increased Akt signaling has been observed in biopsies of 
cancer patients following everolimus treatment, and may help explain why rapalogs have 
largely cytostatic, but not cytotoxic, effects on tumors (Tabernero et al., 2008). Finally, 
mTORC1 inhibition also induces autophagy, which can help maintain cancer cell survival 
poorly vascularized, nutrient poor microenvironments such as in pancreatic tumors. Indeed, 
mTORC1 inhibition also promotes macropinocytosis, whereby extracellular proteins are 
internalized and degraded to provide amino acids for nutrient-starved tumors (Palm et al., 
2015). These data suggest that combining rapalogs with autophagy inhibitors may improve 
efficacy, consistent with a recent phase 1 clinical trial using temsirolomus and the autophagy 
inhibitor hydrochloroquine in melanoma patients, which showed an improvement over 
temsirolomus alone (Rangwala et al., 2014).
In order to address some of the drawbacks of the rapalogs, “second generation,” ATP-
competitive catalytic inhibitors against mTOR have also been developed and are now in 
clinical trials. Unlike rapamycin, these compounds directly inhibit the catalytic activity of 
mTOR and therefore fully suppress both mTORC1 and mTORC2 (Fig. 5B), making them 
more effective than rapalogs in a variety of preclinical cancer models. Although these 
second-generation mTOR inhibitors initially suppress Akt signaling due to inhibition of 
mTORC2, the release of negative feedback on Insulin/PI3K signaling eventually overcomes 
this blockade and Akt is reactivated following long-term treatment (Rodrik-Outmezguine et 
al., 2011). One possible solution to this problem may be the utilization of dual PI3K/mTOR 
inhibitors, which inhibit the closely related catalytic domains of both PI3K and mTOR, 
thereby more fully blocking phosphorylation of both Akt and 4EBP (Fig. 5B). These 
inhibitors have also shown some promise in preclinical and early clinical trial data, but have 
raised concerns over dose-limiting toxicities.
The cases where rapalogs have had the most success to date have generally involved 
mutations in the mTOR pathway itself, such as in TSC1 or MTOR (Iyer et al., 2012; Wagle 
et al., 2014a). Even in these cases, however, an exquisite initial response has been followed 
by additional mutations in the kinase or FRB domains of MTOR, leading to acquired 
resistance (Wagle et al., 2014b). One creative way to overcome these resistance mutations 
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may be with the recently described “third-generation” mTOR inhibitor called “RapaLink,” 
in which the ATP-competitive mTOR inhibitor is chemically linked to rapamycin, enabling 
inhibition of mTOR mutants that are resistant to either MLN0128 or rapamycin alone 
(Rodrik-Outmezguine et al., 2016).
mTOR in Aging
mTOR signaling is strongly implicated in the aging process of diverse organisms including 
yeast, worms, flies, and mammals. This was first observed through studies in the nematode 
C. elegans, which found that reduced expression of the homologs of mTOR (ceTOR, 
formerly let-363) or Raptor (daf-15) extend life span (Vellai et al., 2003; Jia et al., 2004). 
Subsequent genetic studies found that reduced TOR signaling also promotes longevity in 
Drosophila (Kapahi et al., 2004), budding yeast, (Kaeberlin et al., 2005) as well as mice 
(Lamming et al., 2012; Wu et al., 2013). Consistent with this, the mTOR inhibitor 
rapamycin is currently the only pharmacological treatment proven to extend life span in all 
of these model organisms (Bjedov et al., 2010; Harrison et al., 2009; Powers et al., 2006; 
Robida-Stubbs et al., 2012).
The only other intervention shown to extend lifespan in such a wide range of organisms is 
caloric restriction (CR), defined as a reduction in nutrient intake without malnutrition. Given 
the critical role of mTORC1 in sensing nutrients and insulin, this has led many to speculate 
that the beneficial effects of CR on life span are also due to reduced mTORC1 signaling. 
Indeed, CR-like regimens do not further extend life span in yeast, worms, or flies with 
reduced mTOR signaling, suggesting an overlapping mechanism (Kaeberlin et al., 2005; 
Hansen et al., 2007; Kapahi et al., 2004).
While there is now a general consensus that mTOR signaling plays a key role in mammalian 
aging, the mechanism through which this occurs is still unclear. Several lines of evidence 
suggest that the general reduction in mRNA translation during mTORC1 inhibition slows 
aging by reducing the accumulation of proteotoxic and oxidative stress, consistent with the 
observation that loss of the mTORC1 substrate S6K1 also extends life span in mammals 
(Selman et al., 2009). A related possibility is that inhibition of mTORC1 slows aging by 
increasing autophagy, which helps clear damaged proteins and organelles such as 
mitochondria, the accumulation of which are also associated with aging and aging-related 
diseases. Finally, another model suggests that the attenuation of adult stem cells in various 
tissues plays a central role in organismal aging, and mTOR inhibition boosts the self-renewal 
capacity of both hematopoietic and intestinal stem cells in mice (Chen et al., 2009; Yilmaz et 
al., 2012). Ultimately, the importance of mTORC1 signaling in aging likely reflects its 
unique capacity to regulate such a wide variety of key cellular functions (Fig 5C).
The observation that mTOR inhibition extends life span and delays the onset of age-
associated diseases in mammals has led many to speculate that mTOR inhibitors could be 
used to enhance longevity in humans. The major drawback of prolonged rapamycin 
treatment in humans however is the potential for side effects such as immunosuppression 
and glucose intolerance. There is reason for optimism however, as a trial in healthy elderly 
humans using everolimus showed safety and even improved immune function (Mannick et 
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al., 2014), and alternative dosing regimens have been proposed that can promote longevity 
with reduced side effects (Arriola Apelo et al., 2016). Given that many of the negative 
metabolic side effects associated with mTOR inhibitors are due to inhibition of mTORC2, 
while the anti-aging effects are due to inhibition of mTORC1, the development of mTORC1 
specific inhibitors would be particularly beneficial.
Perspectives
It is now clear that the mTOR pathway plays a central role in sensing environmental 
conditions and regulating nearly all aspects metabolism at both the cellular and organismal 
level. In just the last several years, many new insights into both mTOR function and 
regulation have been elucidated, and extensive genetic and pharmacological studies in mice 
have enhanced our understanding of how mTOR dysfunction contributes to disease.
While many inputs to mTORC1 have now been identified and their mechanisms of sensing 
characterized, an integrated understanding of the relative importance of these signals and the 
contexts in which they are important remains largely unclear. For example, it remains 
mysterious which inputs to the TSC complex are dominant and how this depends on the 
physiological context. Similar questions exist for nutrient sensing by the Rag GTPases, 
specifically regarding the purpose of sensing of both lysosomal and cytosolic amino acids, 
as well as the tissues in which the nutrient sensors such as Sestrin2, CASTOR1, and 
SLC38A9 are most important. Such insights will likely require both deeper biochemical 
studies of these complexes in vitro as well as improved mouse models that enable more 
nuanced perturbation and monitoring of these sensors in vivo.
The major focus of mTOR research going forward however will be to address whether these 
molecular insights can improve the therapeutic targeting of mTOR in the clinic. Although 
rapalogs and catalytic mTOR inhibitors have been successful in the context of 
immunosuppression and a small subset of cancer types, clear limitations have arisen which 
limit their utility. Specifically, given the critical functions of mTOR in most human tissues, 
complete catalytic inhibition causes severe dose-limiting toxicities, while rapalogs also 
suffer from the drawbacks associated with lack of tissue specificity and unwanted disruption 
of mTORC2. Future work should focus on the development of mTOR-targeting therapeutics 
outside of these two modalities, such as truly mTORC1-specific inhibitors for use in 
diabetes, neurodegeneration, and life-span extension, or tissue-specific mTORC1 agonists 
for use in muscle wasting diseases and immunotherapy. Such approaches will likely require 
going beyond targeting mTOR directly to instead developing compounds that modulate 
tissue-specific receptors or signaling molecules upstream of mTOR, such as the recently 
characterized amino acid sensors Sestrin2 and CASTOR1, which contain small-molecule 
binding pockets and specifically regulate mTORC1. Ultimately, such insights may enable 
the rational targeting of mTOR signaling to unlock the full therapeutic potential of this 
remarkable pathway.
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Figure 1. mTORC1 and mTORC2
(A) The mTORC1 and mTORC2 signaling pathways.
(B) mTORC1 subunits and respective binding sites on mTOR. The FKBP12-rapamycin. The 
5.9 Å cryo-EM structure of mTORC1 (without DEPTOR and PRAS40, PDB ID: 5FLC) 
from is depicted as a space filling model and colored by subunit.
(C) mTORC2 subunits and respective binding sites on mTOR.
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Figure 2. The mTOR Signaling Network
(A) The signaling pathways upstream of mTORC1 and mTORC2. Positive regulators of 
mTORC1 signaling are shown in yellow, while negative regulators are shown in blue. 
mTORC1 and mTORC2 are shown in green and red, respectively.
(B) The major signaling pathways downstream of mTORC1 signaling in mRNA translation, 
metabolism, and protein turnover.
(C) mTORC1 controls the activity of several transcription factors that can also be 
independently regulated by cell stress.
(D) The major signaling pathways downstream of mTORC2 signaling.
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Figure 3. Evolutionary Conservation of the mTOR Pathway
(A) The nutrient sensing pathway upstream of mammalian mTORC1 (left) and yeast 
TORC1 (right).
(B) Phylogenetic tree depicting the presence (green box) of key mTORC1 regulators in 
various model organisms.
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Figure 4. Physiological Roles of mTOR
(A) mTORC1 controls the balance between anabolism and catabolism in response to fasting 
and feeding.
(B) The effect of cumulative mTORC1 activity on overall health.
(C) The effect of mTORC1 hyperactivation in pancreatic β-cells on glucose tolerance over 
time.
(D) The normal functions of mTORC1 in the liver, muscle, pancreas, and adipose tissue 
(left), and the consequences of chronic mTORC1 inhibition (middle) or activation (right).
(E) Deregulation of mTORC1 signaling in insulin resistance/diabetes, and the effect of 
rapamycin or a theoretical mTORC1 specific inhibitor.
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Figure 5. mTOR in Cancer and Aging
(A) The common tumor suppressors and oncogenes upstream of mTORC1 leading to 
increased mTORC1 signaling in a wide variety of cancers.
(B) The varying effects of rapalogs, catalytic mTOR inhibitors, a combination of an mTOR 
inhibitor and autophagy inhibitor on cancer proliferation and survival.
(C) The role of mTORC1 signaling in aging.
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